
CAR T-cell therapy for treatment of Non-Hodgkin's B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of cancer that originates in the B cells of the immune system. DLBCL is one of the world's most common B-cell cancers and the disease has a rapid progression, which requires treatment to be initiated as soon as possible after the diagnosis is established. ELC-301 is being developed for patients suffering from a particularly severe form of DLBCL or who suffer relapse after several rounds of standard treatment.
Today's standard treatment consists of a combination of chemotherapy and antibodies and 60-70% of patients are cured. In patients who suffer relapse, CAR T-cell therapy is the next step in the treatment ladder. Despite the fact that the disease disappears in many after CAR T-cell treatment, the relapse rate is high in the patient group – up to 50% – and treatment options in the form of more advanced therapies are limited.
Today's approved CAR T-cell therapies target the tumor target CD19 – a common B-cell protein that is overproduced on the surface of cancer cells in DLBCL. In many of the individuals who suffer from relapse, this tumor target disappears and further treatments with the same CAR T therapy therefore become ineffective. ELC-301 instead targets CD20, which is also overrepresented in B-cell lymphoma. By switching targets to CD20, ELC-301 enables the treatment of relapsed patients who are in need of a new effective alternative.
In preclinical studies, ELC-301 has been shown to be able to induce an immune response that kills even those cancer cells that do not express the CAR T-cell antigen.
The Company has an ongoing Phase I/IIa clinical trial, called CARMA, with ELC-301 in a total of 18 cancer patients. The trial is conducted in two parts: a dose-escalation study, which has been completed, and a dose-optimization study. The first part was carried out in three cohorts of three, three and six patients, and aimed to identify the maximum tolerated dose (MTD) of ELC-301. In the second, ongoing part, a total of six patients are being treated in order to define the treatment dose for continued clinical development.
CARMA has been supported by a grant from the European Innovation Council's Accelerator Fund.

A new CAR T-cell therapy for the initial treatment of brain tumors with immune enhancement via the iTANK-platform
Glioblastoma (glioblastoma; GBM) is an aggressive form of brain cancer with a very high mortality rate, the expected survival of people diagnosed is about 15 months. In the US alone, approximately 15,000 individuals are affected by GBM and this form of cancer is expected to become more common, mainly due to the lack of effective cures. An aggravating factor in the development of drugs in the central nervous system is to enable the drug to cross the blood-brain barrier. Due to many setbacks in the pharmaceutical industry's attempts to overcome this challenge, GBM is currently treated primarily through surgery and radiation therapy.
ELC-401 targets the tumor antigen IL13Ra2 – a receptor protein that is overrepresented in GBM. In a preclinical study, the company has been able to show that IL13Ra2 is an effective tumor target for iTANK-enhanced CAR T-cells. The study, published in Nature Communications in 2023, evaluated the synthetic receptor underlying ELC-401. The results showed, among other things, that the CAR T-cells had a potent cell-killing effect and prolonged survival in the disease model.
Thanks to iTANK, ELC-401 is also expected to be able to counteract the highly immunosuppressive microenvironment in glioblastoma and mobilize an immune response against other targets in this heterogeneous form of cancer.
ELC-401 is currently in the clinical planning phase, and the Company is conducting process development and technology transfer of the manufacturing process to the selected manufacturing partner.
Next-generation oncolytic immunotherapy with three combined mechanisms of action.
Elicera's next-generation oncolytic immunotherapy, ELC-201, is based on a genetically modified adenovirus vector, armed with the company's proprietary iTANK-technology and a trans gene for 4-1BBL. The treatment is expected to work synergistically with established immune checkpoint inhibitors and can theoretically be used for the treatment of all injectable solid tumors.
AdVince – Oncolytic virus in a completed Phase I/IIa study, sponsored by Uppsala University, for the treatment of neuroendocrine tumors
Elicera's oncolytic virus AdVince (ELC-100) is based on a genetically modified adenovirus, Ad5PTD, that has been optimized with regards to its ability to selectively infiltrate and replicate in neuroendocrine cancer cells. When new virus particles have formed in enough numbers, tumor cells burst through a so-called immunogenic oncolysis, releasing factors that can also activate the immune system. When the tumor cell dies, an immune response to the cancer is also triggered by the release of neoantigens which are picked up by the patient's antigen-presenting dendritic cells, which then train T-cells in to attack cancer cells wherever they are in the body. In this way, AdVince is expected to achieve a local tumor-killing effect in the injected tumor while simultaneously triggering a long-term and systemic immune response through a T-cell attack on cancer cells in other parts of the body as well.
ELC-301 is currently undergoing a Phase I/IIa clinical trial called CARMA. The study evaluates the safety, optimal dosing and preliminary efficacy of ELC-301 in patients with relapsed or refractory B-cell lymphoma who have received at least two prior lines of standard therapy and have no remaining curative treatment options. The study includes a dose-escalation phase (Phase I) with twelve patients in three cohorts to identify the maximum tolerated dose, followed by further evaluation of six patients in an expansion phase (Phase IIa).
The Phase I part of the study has been completed and showed that eight of twelve patients achieved a complete metabolic response (CMR, disease-free) as their best response during follow-up, and eleven patients had an objective tumor response. Six patients remained in CMR at their most recent assessment. The disease control rate was 100% and the objective response rate was 92% (11/12).
ELC-100 has completed a Phase I/IIa clinical trial, sponsored by Uppsala University (ClinicalTrials.gov Identifier: NCT02749331)*, where the primary objective was to evaluate the safety of the treatment and determine the maximum tolerated dose for continued clinical development.
inal data from the Phase I/IIa clinical trial showed that ELC-100 was generally well tolerated, with no dose-limiting toxicity observed. Notably, the study also showed promising signs of efficacy, including partial tumor responses in two of eight patients evaluable for efficacy, providing early evidence of antitumor activity in this highly treatment-resistant patient population.